TABLE 3.
Association of Gliflozin use with demographic and clinical factors.
| Variable | Category | Gliflozin use (No) N (%) | Gliflozin use (Yes) N (%) | Total N (%) | P-value |
|---|---|---|---|---|---|
| Gender | Female | 53 (72.6) | 20 (27.4) | 73 (100) | 0.203 |
| Male | 117 (64.3) | 65 (35.7) | 182 (100) | ||
| Age groups (years) | 27–40 | 13 (76.5) | 4 (23.5) | 17 (100) | 0.089 |
| 41–55 | 52 (67.5) | 25 (32.5) | 77 (100) | ||
| 56–70 | 55 (57.9) | 40 (42.1) | 95 (100) | ||
| >70 | 50 (75.8) | 16 (24.2) | 66 (100) | ||
| BMI groups | 18.5–24.99 (Normal) | 50 (83.3) | 10 (16.7) | 60 (100) | 0.002 a |
| 25–29.9 - ≥30 (Overweight - Obese) | 120 (61.5) | 75 (38.5) | 195 (100) | ||
| HbA1c Group | Less than <5.7 (normal) | 26 (78.8) | 7 (21.2) | 33 (100) | <0.001 a |
| 5.7–6.4 (Prediabetes) | 38 (79.1) | 10 (20.9) | 48 (100) | ||
| ≥6.5 (Diabetes) | 47 (49.0) | 49 (51.0) | 96 (100) | ||
| Diagnosed with diabetes | Yes | 110 (60.1) | 73 (39.9) | 183 (100) | <0.001 a |
| No | 58 (85.3) | 10 (14.7) | 68 (100) | ||
| Comorbidity/complications | HF | 25 (38.5) | 40 (61.5) | 65 (100) | <0.001 a |
| CKD | 145 (76.3) | 45 (23.7) | 190 (100) | ||
| CKD with diabetes | 97 (70.8) | 40 (29.2) | 137 (100) | <0.001 a | |
| CKD with no diabetes | 46 (92.0) | 4 (8.0) | 50 (100) | ||
| HF with diabetes | 13 (28.3) | 33 (71.7) | 46 (100) | ||
| HF with no diabetes | 12 (66.7) | 6 (33.3) | 18 (100) |
a
Significant value. HF, Heart Failure; CKD, chronic kidney disease.